Docetaxel micellar is a clinical phase drug candidate being developed for advanced prostate cancer in a novel formulation that combines the well-established cytotoxin docetaxel in combination with XR-17 enabling Docetaxel to be administered without solvents.
A clinical trial with Vivesto’s formulation of Docetaxel micellar in patients with metastatic prostate cancer is conducted at major hospitals in Switzerland with the Swiss Group for Clinical Cancer Research, SAKK as sponsor. In August 2023, Vivesto announced early termination of patient enrollment and the study closed its accrual after enrollment of 11 of the planned 18 patients, since Vivesto believed that the data generated will be sufficient ahead of switching into development with a new formulation based on its improved XR-18 micelle technology platform.
